Artelo Biosciences received a patent allowance from the European Patent Office for its drug candidate ART27.13, which is evaluated for cancer-related anorexia.
2 reports, 1 independent
Updated Aug 17
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Artelo Biosciences received a patent allowance from the European Patent Office for its drug candidate ART27.13, which is evaluated for cancer-related anorexia.
Coverage
Newest first; wire copies grouped- GlobeNewswireArtelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13 Extends Patent Protection Through December 2041 A